ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
ELITE PHARMACEUTICALS INC /NV/
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.25−0.00 (-1.37%)
Close on Oct 19, 2026
- Market cap
- $283.02M
- P/E (TTM)
- 5.0
- Dividend yield
- –
Elite Pharmaceuticals statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Market Cap | $270.10M | $166.30M |
| Enterprise Value | $231.16M | $88.19M |
| PE Ratio | 5.02 | 20.44 |
| PS Ratio | 1.92 | 3.65 |
| PB Ratio | 2.58 | 2.03 |
| P/TBV Ratio | 2.70 | 2.29 |
| P/FCF Ratio | 15.41 | 17.44 |
| P/OCF Ratio | 14.18 | 12.98 |
Enterprise value
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| EV / Sales | 1.64 | 2.51 |
| EV / EBITDA | 6.42 | 14.65 |
| EV / EBIT | 6.62 | 19.00 |
| EV / FCF | 13.19 | 20.86 |
Income (trailing twelve months)
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Revenue | $141.01M | $58.34M |
| Gross Profit | $61.31M | $105.94M |
| Operating Income | $34.94M | -$21.40M |
| Pretax Income | $65.10M | -$14.34M |
| Net Income | $56.67M | -$22.46M |
| EBITDA | $35.99M | -$16.91M |
| EPS (Diluted) | $0.05 | -$0.83 |
Margins
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Gross Margin | 43.5% | 52.9% |
| Operating Margin | 24.8% | -44.0% |
| Pretax Margin | 46.2% | -13.3% |
| Profit Margin | 40.2% | -40.2% |
| EBITDA Margin | 25.5% | -30.2% |
| FCF Margin | 12.4% | -9.27% |
Returns
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Return on Equity (ROE) | 74.3% | -53.2% |
| Return on Assets (ROA) | 45.2% | -40.9% |
| Return on Invested Capital (ROIC) | 66.3% | -32.4% |
| Return on Capital Employed (ROCE) | 32.0% | -38.1% |
Growth
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 33.7% | 5.96% |
| FCF Growth (YoY) | -2.76% | 2.34% |
| Revenue Growth (3Y CAGR) | 63.3% | 2.25% |
| Revenue Growth (5Y CAGR) | 42.4% | 6.48% |
Balance sheet
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $38.94M | $61.43M |
| Net Cash (Debt) | $38.94M | $15.35M |
| Net Cash Per Share | $0.04 | $0.66 |
| Equity (Book Value) | $104.83M | $49.09M |
| Book Value Per Share | $0.10 | $1.37 |
| Tangible Book Value | $100.04M | $23.52M |
| Working Capital | $84.05M | $76.81M |
Financial position
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Current Ratio | 3.76 | 3.34 |
| Quick Ratio | 2.94 | 2.44 |
| Interest Coverage | 318.43 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Operating Cash Flow | $19.04M | -$12.35M |
| Capital Expenditures | -$1.52M | -$1.08M |
| Free Cash Flow | $17.53M | -$20.22M |
| FCF Per Share | $0.02 | -$0.42 |
Efficiency
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Asset Turnover | 1.12 | 0.39 |
| Inventory Turnover | 3.66 | 2.70 |
| Revenue Per Employee | $2.17M | $404.87K |
| Profits Per Employee | $871.82K | -$703.34K |
| Employee Count | 65 | 74 |
Dividends and yields
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Earnings Yield | 21.0% | -23.3% |
| FCF Yield | 6.49% | -8.72% |
Shares
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Shares Outstanding | 1,077,140,000 | 58,127,000 |
| Shares Change (YoY) | 7.64% | 10.9% |
| Shares Change (QoQ) | 0.00% | 0.54% |
| Float | 1,063,550,000 | 49,136,700 |
| Shares Held by Insiders | 1.26% | 11.6% |
| Shares Held by Institutions | 0.00% | 59.4% |
Taxes
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Income Tax | $8.43M | $79.87K |
| Effective Tax Rate | 12.9% | 20.6% |
Scores
| Measure | Elite Pharmaceuticals | Industry median |
|---|---|---|
| Graham Number | $0.33 | $18.73 |
| Graham Upside | 32.0% | -45.1% |
| Altman Z-Score | 6.51 | -0.22 |
| Piotroski F-Score | 7 | 4 |
Calculated by StockData from Elite Pharmaceuticals's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.